CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Allopurinol +1 moredrug
Likely dose
Allopurinol 300 mg intravenous infusionAI-extracted
Key inclusion· 6
  • ✓Age >18 years
  • ✓Clinical diagnosis of chronic heart failure
  • ✓Ejection fraction <40% by imaging (echo, MUGA, or cath)
  • ✓No significant coronary disease on cardiac catheterization
Key exclusion· 6
  • ✕Metallic implant precluding MR evaluation
  • ✕Unable to lie flat for MR study
  • ✕Receiving other investigational drugs
  • ✕Allergy to allopurinol

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00181155
NCT00181155Phase 2Completed
CompareCT.gov

Effects of Xanthine Oxidase Inhibition on Mechano-Energetic Coupling in Heart Failure

Johns Hopkins University·interventional·Posted Sep 16, 2005·Updated May 30, 2017

In Brief

A Phase 2 clinical trial evaluating Allopurinol and Placebo for Congestive Heart Failure. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongestive Heart Failure
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartNov 1, 2004
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 20.8 years ago

Interventions

Allopurinoldrug

intravenous infusion of allopurinol (300mg)

Placebodrug

intravenous infusion of 50 ml dose of 5% dextrose